This post is presented by our media partner Grow Opportunity
View the full article here.
(Globe Newswire) Vancouver — Segra International Corp., an agriculture technology company has received approval of its analytical testing licence from Health Canada under the Cannabis Act and Cannabis Regulations.
Segra’s molecular lab opened in 2017 to provide pathogen diagnostic testing and cultivar identification services for our tissue culture facility. These services have become a critical part of the quality assurance process that underlays our Verified Clean Stock™ program, and now includes ten Real Time PCR-based plant pathogen assays, including for HLVd.
Having in-house molecular testing services is an important differentiator for Segra and provides our customers with peace of mind that they receive heathy, true to type, disease-free plantlets. After performing nearly 10,000 assays in the 2021-2022 fiscal year, they have upgraded their lab to increase capacity and now offer these services to our customers and other third parties looking for better crop surveillance tools.
The recently awarded cannabis analytical testing licence marks the official launch of Segra Molecular Lab Services, which can now test cannabis plant materials for licensed cannabis producers seeking pathogen testing and DNA fingerprinting services.
Advertisement
“We have been using Segra’s molecular lab for internal purposes and after feedback from customers, it’s time to make these value-added services available for all LPs in an effort to help mitigate cultivation risks, increase supply chain security and to monitor your fungal pathogen, virus and viroid load, all standard best practices in other commercially grown crops.” — Jamie Blundell, CEO, Segra
This post was originally published by our media partner here.
